Trial Profile
Open-label, placebo-controlled, parallel group study in healthy volunteers to evaluate the effects of two single MT 400 [naproxen sodium/sumatriptan] or naproxen sodium tablets administered two hours apart on chromosomal aberrations in peripheral blood lymphocytes
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Jul 2023
Price :
$35
*
At a glance
- Drugs Naproxen sodium/sumatriptan (Primary) ; Naproxen sodium
- Indications Migraine
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 02 Feb 2008 New trial record.